Price
Target price
€62.32
€62.32
0.420%
0.26
0.420%
€76.30
17:15 / Tradegate
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Halozyme Therapeutics Inc. Stock
Halozyme Therapeutics Inc. gained 0.420% compared to yesterday.
The stock is one of the favorites of our community with 21 Buy predictions and 1 Sell predictions.
As a result the target price of 76 € shows a positive potential of 21.95% compared to the current price of 62.32 € for Halozyme Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Halozyme Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 0.420% | 8.763% | 9.880% | 30.351% | 5.904% | 101.102% | 91.307% |
| Ligand Pharmaceuticals | 0.970% | 1.980% | 4.569% | 120.321% | 24.096% | 202.941% | 122.270% |
| United Therapeutics | -0.460% | -1.202% | -6.048% | 66.923% | 11.608% | 133.431% | 228.897% |
| Ionis Pharmaceuticals Inc. | 0.220% | -1.464% | 0.466% | 108.654% | -4.915% | 59.398% | 127.696% |
Comments
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its price target lowered by Morgan Stanley from $96.00 to $93.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
News
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
Key Points
- Interested in argenex SE? Here are five stocks we like better.
- argenx said its main priorities are revenue growth, profitability and execution as it expands the VYVGART franchise
Halozyme Therapeutics Q1 Earnings Call Highlights
Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
